Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
BEFREE |
Pharmacogenetics of Dopamine β-Hydroxylase in cocaine dependence therapy with doxazosin.
|
29498170 |
2019 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
BEFREE |
Disulfiram (Antabuse), an acetaldehyde dehydrogenase and dopamine-beta hydroxylase inhibitor, has shown promise in preclinical and clinical studies as a pharmacotherapy for cocaine addiction.
|
29963872 |
2018 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
PSYGENET |
Randomized clinical trial of disulfiram for cocaine dependence or abuse during buprenorphine treatment.
|
24462581 |
2014 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
PSYGENET |
The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.
|
24809448 |
2014 |
Cocaine Dependence
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
The influence of dopamine β-hydroxylase gene polymorphism rs1611115 on levodopa/carbidopa treatment for cocaine dependence: a preliminary study.
|
24809448 |
2014 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
PSYGENET |
This study indicates that the DBH genotype of a patient could be used to identify a subset of individuals for which disulfiram treatment might be an effective pharmacotherapy for cocaine dependence.
|
22906516 |
2013 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
PSYGENET |
DBH gene as predictor of response in a cocaine vaccine clinical trial.
|
23458673 |
2013 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
BEFREE |
Disulfiram is a cocaine addiction pharmacotherapy that inhibits dopamine β-hydroxylase (DβH) and reduces norepinephrine production.
|
23849431 |
2013 |
Cocaine Dependence
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that a patient's DBH genotype could be used to identify a subset of individuals for whom vaccine treatment may be an effective pharmacotherapy for cocaine dependence.
|
23458673 |
2013 |
Cocaine Dependence
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that the DBH genotype of a patient could be used to identify a subset of individuals for which disulfiram treatment might be an effective pharmacotherapy for cocaine dependence.
|
22906516 |
2013 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
PSYGENET |
Pharmacogenetic randomized trial for cocaine abuse: disulfiram and α1A-adrenoceptor gene variation.
|
23849431 |
2013 |
Cocaine Dependence
|
0.390 |
Biomarker
|
disease |
BEFREE |
Several studies have looked for a link between cocaine addiction and the genes of the dopaminergic system: the genes DRD2, COMT, SLC6A3 (coding for the dopamine transporter DAT) and DBH (coding for the dopamine beta hydroxylase) but unfortunately very few well established results.
|
20801583 |
2010 |
Cocaine Dependence
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
We genotyped the Int8 and 3'UTR variable number of tandem repeats of the dopamine transporter gene (DAT1/SLC6A3), the TaqIA (rs1800497) and TaqIB (rs1079597) SNP polymorphisms within the dopamine receptor D2 gene and the 19-bp insertion/deletion and c.444G>A (rs1108580) polymorphisms of the dopamine β-hydroxylase gene (DBH) in a Spanish sample of 169 patients with cocaine addiction and 169 sex-matched controls.
|
20505554 |
2010 |
Cocaine Dependence
|
0.390 |
GeneticVariation
|
disease |
BEFREE |
Disulfiram and methylphenidate pharmacotherapies for cocaine addiction are optimized by considering polymorphisms affecting DbetaH and DAT1 respectively.
|
19462300 |
2009 |